Welcome to our dedicated page for Medexus Pharmace news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmace stock.
Medexus Pharmaceuticals Inc. reports news on its specialty pharmaceutical portfolio and North American commercial operations. The company's updates center on GRAFAPEX (treosulfan) for Injection in the United States, financial results, and product-level trends across therapeutic areas that include hematology and hematology-oncology, rheumatology, allergy, and dermatology.
Medexus news also covers capital allocation and capital structure actions, including credit facilities, warrant expirations, and normal course issuer bid activity, along with shareholder meeting results, conference calls, and management participation in investor conferences.
Medexus (TSX: MDP, OTCQX: MEDXF) reported fiscal Q1 2027 net revenue of $28.6 million, up 16.3% year over year, driven mainly by GRAFAPEX, IXINITY and Rasuvo. Product-level net revenue from GRAFAPEX (treosulfan) reached $4.9 million, exceeding related personnel and infrastructure investments of $3.2 million.
Adjusted EBITDA was $4.7 million (+38.2%), operating income was $2.1 million (+133.3%), and net income was $0.5 million, similar to the prior year. Gross margin was 55.6% and Adjusted Gross Margin 63.8%, both affected by a prior-year one-time royalty benefit.
Available liquidity at June 30, 2026 was $5.3 million in cash with no undrawn revolver capacity then, and operating activities used $0.7 million of cash, mainly due to settling previously accrued expenses. Medexus guided to $30–32 million of GRAFAPEX product-level net revenue for fiscal 2027 and reiterated a long-term GRAFAPEX annual net revenue expectation of $100–175 million within five years after launch.
Operationally, GRAFAPEX underlying patient demand grew 23% versus fiscal Q4 2026 and 118% versus fiscal Q1 2026. Medexus also secured exclusive Canadian rights to commercialize UM171 Cell Therapy (Zemcelpro) and amended its NBC Credit Agreement to add a $2.6 million letter of credit facility and draw $2.0 million to fund the UM171 upfront payment.
Medexus Pharmaceuticals (TSX: MDP, OTCQX: MEDXF) will host a conference call at 8:00 a.m. ET on Tuesday, August 11, 2026 to discuss results for its first fiscal quarter ended June 30, 2026. Medexus expects to file its Q1 2027 financial statements and MD&A after markets close on August 10, 2026. Investors can join via toll-free and international dial-in numbers, or through a live webcast on the company’s investor website. Telephone replay is available until August 25, 2026, and webcast replay until August 11, 2027.
Medexus (OTCQX: MEDXF) reported fiscal 2026 net revenue of $99.3 million, down 8.3% year over year, and Adjusted EBITDA* of $16.5 million, down 18.3%. GRAFAPEX generated $11.6 million product-level net revenue, exceeding $11.2 million in launch investments and supporting higher gross margins. Net loss was $2.4 million, while cash from operations reached $18.9 million. GRAFAPEX product-level net revenue is expected between $30–32 million in fiscal 2027, with long‑term annual potential above $100 million within five years of launch. Medexus also secured Canadian rights to UM171 Cell Therapy.
Medexus Pharmaceuticals (OTCQX: MEDXF) will host a conference call at 8:00 a.m. ET on June 26, 2026 to review results for its fourth fiscal quarter and fiscal year ended March 31, 2026.
Financial statements and MD&A are expected to be filed after markets close on June 25, 2026.
Medexus (OTCQX: MEDXF) entered a license and supply agreement with ExCellThera and Cordex Biologics, securing exclusive Canadian rights to commercialize UM171 Cell Therapy, conditionally approved in Europe as Zemcelpro® (dorocubicel) for hematological malignancies.
Medexus paid an initial US$2 million, will owe royalties and milestones, and does not expect Canadian commercialization before 2028–2031, pending Health Canada approval and completion of a Cordex-led phase 3 trial.
Medexus (OTCQX: MEDXF) provided an April 15, 2026 business update on GRAFAPEX (treosulfan) commercialization, capital actions and upcoming investor conferences.
Key facts: as of March 31, 2026, 56 institutions (31% of 180 U.S. transplant centers) made positive formulary decisions and 64 centers have ordered product; Medexus repurchased 710,100 shares for C$2.1M and all 2023 warrants expired April 6, 2026.
Medexus (OTCQX: MEDXF) reported fiscal Q3 2026 results and a business update for the quarter ended December 31, 2025.
Key points: Net revenue was $25.3M (Q3) and $74.7M (nine months). GRAFAPEX product-level revenue was $2.0M (Q3) and $8.2M (nine months) versus $8.5M of launch investment year-to-date. Adjusted EBITDA was $4.5M (Q3). Available liquidity: $15.0M.
Medexus (OTCQX: MEDXF) will host a conference call at 8:00 AM ET on Thursday, February 12, 2026 to discuss results for its third fiscal quarter ended December 31, 2025. The company expects to file its financial statements and MD&A after markets close on February 11, 2026.
A live webcast will be available on the Medexus Investors site with dial-in access for Canadian/U.S. and international callers. A telephone replay and archived webcast will be available through specified dates, with the webcast replay available until February 12, 2027.
Medexus (OTCQX: MEDXF / TSX: MDP) announced a normal course issuer bid (NCIB) accepted by the Toronto Stock Exchange, allowing purchases of up to 2,983,650 common shares, approximately 10% of the public float. As of November 12, 2025 there were 32,420,060 shares outstanding and a public float of 29,836,506. Purchases may begin on November 24, 2025 and run through November 23, 2026, will be funded from the company's general funds, executed on the TSX or alternative Canadian trading systems, and any shares purchased will be cancelled. The six‑month ADTV to October 31, 2025 was 40,066, limiting daily purchases to 10,016 shares under TSX rules, excluding block purchase exceptions.
Medexus (OTCQX: MEDXF) entered a new senior secured credit agreement with National Bank of Canada providing a US$21.0 million term loan and a US$5.0 million revolving loan, plus a US$10.0 million delayed draw feature and a US$15.0 million uncommitted accordion. The facilities mature on November 17, 2029. Medexus used net proceeds to repay existing senior secured facilities due March 2026. Borrowings bear adjusted term SOFR (or other base rate) plus a quarterly margin tied to consolidated net leverage; the initial weighted average interest rate is 6.74% versus the prior 6.95%. Medexus also intends to seek TSX approval for an NCIB to buy up to 10% of its public float over 12 months.